Advances in ADT: Part II (2023)

COMPLIMENTARY CME VIRTUAL COURSES!


Advances in ADT: Part II (2023) is a series of educational activities for the urologic care team to further address the identified educational gaps and barriers in advanced prostate cancer care. This educational series has been designed to update urologists and advanced practice providers (APPs) on the latest advancements in androgen deprivation therapy (ADT) and prostate cancer treatment. This educational initiative is comprised of multiple formats, including two live virtual courses and on-demand webcasts. These live virtual courses, one designed specifically for urologists and the other for APPs, will feature a multidisciplinary panel, engaging in a lively discussion.

Additionally, the activity developed specifically for urologists will be released as an episode on the very successful AUAUniversity Podcast. For a deeper dive into select topics in ADT and advanced prostate cancer care, the AUA will also produce two additional episodes for release on the AUAUniversity Podcast.


Join us on:

Tuesday, September 26, 2023          A Guide for APPs

Thursday, September 28, 2023        A Guide for Urologists


 

ACKNOWLEDGEMENT

This educational activity is supported by an independent educational grant from:

  • Myovant Sciences LTD
  • Pfizer, Inc.

Target Audience

  • Urologist
  • Advanced Practice Provider (Nurse Practitioners, Physician Assistants, Nurse Navigators)

Learning Objectives

At the conclusion of ADT Part II: A Guide for Urologists, participants will be able to:

  1. Recognize and characterize different disease states for advance prostate cancer including M0 HSPC, M1 HSPC, M0 CRPC, and M1 CRPC.
  2. Discuss the role of a multidisciplinary shared team approach for the diagnosis and management of advanced prostate cancer.
  3. Facilitate discussions with patients and caregivers regarding treatment intensification for advanced prostate cancer.
  4. Identify the role of combination therapy with ADT and additional systemic therapy to yield optimal survival outcomes for metastatic prostate cancer.
  5. Differentiate mechanisms of action and side effects when ADT is delivered via GnRH agonists vs. antagonists.

At the conclusion of ADT Part II: A Guide for APPs, participants will be able to:

  1. Recognize the need for a multidisciplinary team to provide care for patients with advanced prostate cancer.
  2. Classify stages of advanced prostate cancer based on clinical and radiographic modalities.
  3. Apply treatment strategies for different stages of advanced prostate cancer based on current guidelines.
  4. Evaluate and manage comorbid conditions for patients with advanced prostate cancer on systemic therapies.
  5. Describe the role of genetic testing to guide therapies for patients with advanced prostate cancer.
  6. Assess treatment barriers and access to care to therapies for advanced prostate cancer.

 

Course summary
Course opens: 
07/17/2023
Course expires: 
09/28/2026
Rating: 
4

Education Council Disclosures

PDF iconEducation Council Disclosures

COI Review Work Group Disclosures

PDF icon COI Review Work Group Disclosures_2023.pdf

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

 
Status
Price
Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
Please login or register to take this course.

Registration for these Live Webinars is complimentary. 

If you are interested in participating in one or more of the live virtual courses, please click on the name of each course above and complete the registration process for each one, outlined under the “Take Course” tab. Each course has its own distinct ZOOM link that you will need to join the virtual course.

 


Attendee Information & Policies

AUA Anti-Harassment Policy

AUA Commitment: AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress.

Reporting Harassment: It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, at jskorepa@AUAnet.org or Maureen E. Cones, Esq., AUA General Counsel, at mcones@auanet.org or use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly. 

The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy.

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA).

Consent to Use of Photographic Images: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.

Audio, Video, Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.